A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study (vol 27, pg 318, 2010)

被引：3
|
作者：
Filozof, C.
Gautier, J-F
机构：
来源：
DIABETIC MEDICINE | 2013年 / 30卷 / 05期
关键词：
D O I：
10.1111/dme.12167
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：632 / 632
页数：1
相关论文
共 50 条
  • [31] Efficacy of a Combination of Metformin and Vildagliptin in Comparison to Metformin Alone in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Evidence Study
    Mohan, Viswanathan
    Zargar, Abdul
    Chawla, Manoj
    Joshi, Ameya
    Ayyagari, Usha
    Sethi, Bipin
    Gaurav, Kumar
    Patted, Usha Rani H.
    Bhagat, Seema Vikas
    Mane, Amey Ishwara
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 2925 - 2933
  • [32] EFFICACY AND SAFETY OF VILDAGLIPTIN AND TENELIGLIPTIN IN PATIENTS OF TYPE 2 DIABETS MELLITUS INADEQUATELY CONTROLLED ON STABLE DOSES OF METFORMIN
    Rizvi, N.
    Ahmad, J.
    Ahmad, F.
    Siddiqui, S. S.
    Khan, B. H.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (04): : 1629 - 1634
  • [33] Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
    Jabbour, Serge A.
    Frias, Juan P.
    Hardy, Elise
    Ahmed, Azazuddin
    Wang, Hui
    Ohman, Peter
    Guja, Cristian
    DIABETES CARE, 2018, 41 (10) : 2136 - 2146
  • [34] Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. (vol 11, pg 157, 2009)
    Ferrannini, E.
    Fonseca, V
    Zinman, B.
    DIABETES OBESITY & METABOLISM, 2009, 11 (04): : 405 - 405
  • [35] Efficacy and safety of saxagliptin plus metformin versus acarbose plus metformin in type 2 diabetes patients inadequately controlled with metformin monotherapy
    Du, J.
    Liang, L.
    Fang, H.
    Xu, F.
    Li, W.
    Shen, L.
    Mu, Y.
    DIABETOLOGIA, 2016, 59 : S372 - S372
  • [36] Efficiency and safety of transfer of type 2 diabetes patients inadequately controlled on metformin alone to combined therapy with metformin and diabeton MB
    Ametov, A. S.
    Bogdanova, L. N.
    DIABETES MELLITUS, 2009, 12 (04): : 68 - 71
  • [37] A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy
    Marcelo R. Nasser Hissa
    Lilian Loureiro Albuquerque Cavalcante
    Sergio Botelho Guimarães
    Miguel Nasser Hissa
    Diabetology & Metabolic Syndrome, 7
  • [38] Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin
    Ba, Jianming
    Han, Ping
    Yuan, Guoyue
    Mo, Zhaohui
    Pan, Changyu
    Wu, Fan
    Xu, Lei
    Hanson, Mary E.
    Engel, Samuel S.
    Shankar, R. Ravi
    JOURNAL OF DIABETES, 2017, 9 (07) : 667 - 676
  • [39] A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy
    Nasser Hissa, Marcelo R.
    Albuquerque Cavalcante, Lilian Loureiro
    Guimaraes, Sergio Botelho
    Hissa, Miguel Nasser
    DIABETOLOGY & METABOLIC SYNDROME, 2015, 7
  • [40] A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone
    Jung, Chan-Hee
    Rhee, Eun-Jung
    Lee, Won-Young
    Min, Kyung Wan
    Shivane, Vyankatesh K.
    Sosale, Aravind R.
    Jang, Hak Chul
    Chung, Choon Hee
    Nam-Goong, Il Seong
    DIABETES OBESITY & METABOLISM, 2018, 20 (06): : 1535 - 1541
12345